KHKevin Hollevoet

Kevin Hollevoet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin Hollevoet has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fibulin-3 as a Biomarker for Pleural Mesothelioma

    by Kevin Hollevoet, Elad Sharon

    To the Editor: Pass et al. (Oct. 11 issue)1 report on fibulin-3 as a new soluble biomarker for malignant mesothelioma. The diagnostic accuracy of plasma levels of fibulin-3 in the Detroit and New York cohorts (area under the receiver-operating-characteristic curve [AUC], 0.99) exceeded that of any previously reported marker. In the external validation cohort, however, the diagnostic accuracy surprisingly decreased (AUC, 0.87). This marked decrease was probably due to differences in the study population, although the study showed no association between plasma fibulin-3 levels and common patient characteristics. To fully comprehend the potential and limitations of this new biomarker, researchers . . .


  • Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis

    by Kevin Hollevoet, Johannes B. Reitsma, Jenette Creaney, Bogdan D. Grigoriu, Bruce W. Robinson, Arnaud Scherpereel, Alfonso Cristaudo, Harvey I. Pass, Kristiaan Nackaerts, José A. Rodríguez Portal, et al.

    Purpose: Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. Methods: The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. IPD of 4,491 individuals were collected, including several control groups and 1,026 patients with malignant pleural mesothelioma. Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis. Results: At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. The resulting area under the ROC curve was 0.77 (95% CI, 0.73 to 0.81). At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% to 40%). Conclusion: In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research.


  • Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum

    by Kevin Hollevoet, Dirk Bernard, Frank De Geeter, Natascha Walgraeve, Anja Van Den Eeckhaut, Raymond Vanholder, Christophe Van de Wiele, Veronique Stove, Jan P. van Meerbeeck, Joris R. Delanghe

    We enrolled 66 individuals (49 men and 17 women; median age, 58 years; range, 24–80 years), who were referred for measurement of 51Cr-EDTA clearance to estimate the GFR. We excluded patients with asbestos-related diseases/malignancies, patients with endometrial, ovarian, cervix, lung, breast, pancreatic, or gastrointestinal cancer, and patients with leukemia, because these conditions can overexpress mesothelin (3)(4). The study was approved by the ethics committee of both participating hospitals, and participants gave written informed consent. In addition, we analyzed GFR data from 51 chemotherapy-naive mesothelioma patients (47 men and 4 women; median age, 63 years; range, 45–79 years) who had undergone treatment at our institution between 2003 and 2008.